Objective: The primary objective of this study was to estimate the incidence of treatment failure (TF) to protease inhibitor monotherapies (PI/r-MT) with lopinavir/ritonavir (LPV/r) or darunavir/ritonavir (DRV/r). Design: A multicenter cohort of HIV-infected patients with viral load (VL) â¤50 copies/mL, who underwent a switch from any triple combination therapy to PI/r-MT with either LPV/r or DRV/r. Methods: VL was assessed in each center according to local procedures. Residual viremia was defined by any HIV-RNA value detectable below 50 copies/mL by a Real-Time PCR method. Standard survival analysis was used to estimate the rate of TF (defined by virological failure or interruption of monotherapy or reintroduction of combination therapy). A multivariable Cox regression analysis with automatic stepwise procedures was used to identify factors independently associated with TF among nadir and baseline CD4+ counts, residual viremia, time spent with <50 HIV-RNA copies/mL before switch, history of virological failure, HCV co-infection, being on a PI/r and hemoglobin concentrations at baseline. Results: Six hundred ninety patients fulfilled the inclusion criteria and were included in this analysis. Their median follow-up was 20 (10-37) months. By month 36, TF occurred in 176 (30.2%; 95% CI:25.9-34.5) patients. Only CD4+ nadir counts (adjusted hazard ratio [aHR] = 2.03 [95% CI: 1.35, 3.07] for counts â¤100 vs. >100 cells/μL) and residual viremia (aHR = 1.48 [95% CI: 1.01-2.17] vs. undetectable VL) were independently associated to TF. Conclusions: Residual viremia and nadir CD4+ counts <100 cells/μL should be regarded as the main factors to be taken into account before considering switching to a PI/r-MT.
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients / Gianotti, Nicola; Cozzi-Lepri, Alessandro; Antinori, Andrea; Castagna, Antonella; De Luca, Andrea; Celesia, Benedetto Maurizio; Galli, Massimo; Mussini, Cristina; Pinnetti, Carmela; Spagnuolo, Vincenzo; D'Arminio Monforte, Antonella; Ceccherini-Silberstein, Francesca; Andreoni, Massimo. - In: PLOS ONE. - ISSN 1932-6203. - 12:2(2017), pp. e0171611-e0171611.
Data di pubblicazione: | 2017 |
Titolo: | Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients |
Autore/i: | Gianotti, Nicola; Cozzi-Lepri, Alessandro; Antinori, Andrea; Castagna, Antonella; De Luca, Andrea; Celesia, Benedetto Maurizio; Galli, Massimo; Mussini, Cristina; Pinnetti, Carmela; Spagnuolo, Vincenzo; D'Arminio Monforte, Antonella; Ceccherini-Silberstein, Francesca; Andreoni, Massimo |
Autore/i UNIMORE: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1371/journal.pone.0171611 |
Rivista: | |
Volume: | 12 |
Fascicolo: | 2 |
Pagina iniziale: | e0171611 |
Pagina finale: | e0171611 |
Codice identificativo ISI: | WOS:000394423800032 |
Codice identificativo Scopus: | 2-s2.0-85012181060 |
Codice identificativo Pubmed: | 28192453 |
Citazione: | Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients / Gianotti, Nicola; Cozzi-Lepri, Alessandro; Antinori, Andrea; Castagna, Antonella; De Luca, Andrea; Celesia, Benedetto Maurizio; Galli, Massimo; Mussini, Cristina; Pinnetti, Carmela; Spagnuolo, Vincenzo; D'Arminio Monforte, Antonella; Ceccherini-Silberstein, Francesca; Andreoni, Massimo. - In: PLOS ONE. - ISSN 1932-6203. - 12:2(2017), pp. e0171611-e0171611. |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
Refining.pdf | Versione dell'editore (versione pubblicata) | Open Access Visualizza/Apri |

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris